Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jazz Pharmaceuticals PLC

www.jazzpharma.com

Latest From Jazz Pharmaceuticals PLC

Sanofi Follows Charity Copay Settlement Playbook – But With Smaller Payment

Sanofi agrees to pay $11.5m and enter new corporate integrity agreement to mitigate risk and establish independent charity budget.

Advertising, Marketing & Sales Enforcement

Finance Watch: Coronavirus-Related Stock Market Meltdown Didn’t Stop Passage Bio IPO

Public Company Edition: The gene therapy firm’s IPO priced at $18 and ended its first day up 23.3% at $22.20 but fell to $21.50 when stocks recovered on 2 March. Also, RedHill raised $115m for product launches and Movantik purchase, and Avadel raised $65m to compete with Jazz.

Financing Gene Therapy

EU Accelerated Assessment Tracker

EU marketing applications from Vertex and Roche have reverted to standard review timelines at the European Medicines Agency. The outcomes of three fast-track requests that companies have made for their planned filings are still unknown.

Europe Drug Review

GSK: Please, EMA, Can We Have Some More?

Hot on the heels of winning EU fast-track review status for belantamab mafodotin, GlaxoSmithKline has asked the European Medicines Agency to grant accelerated assessment to another of its planned marketing applications.

Europe Approvals
See All

Company Information

UsernamePublicRestriction

Register